Last reviewed · How we verify
Low-dose acetylsalicylic acid
Low-dose acetylsalicylic acid inhibits platelet aggregation by irreversibly blocking cyclooxygenase-1 (COX-1), reducing thromboxane A2 production.
Low-dose acetylsalicylic acid inhibits platelet aggregation by irreversibly blocking cyclooxygenase-1 (COX-1), reducing thromboxane A2 production. Used for Primary prevention of cardiovascular events, Secondary prevention of myocardial infarction and stroke, Atrial fibrillation for stroke prevention.
At a glance
| Generic name | Low-dose acetylsalicylic acid |
|---|---|
| Also known as | 125mg acetylsalicylic acid |
| Sponsor | Barcelona Institute for Global Health |
| Drug class | Antiplatelet agent / NSAID |
| Target | Cyclooxygenase-1 (COX-1) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Acetylsalicylic acid (aspirin) acetylates serine residues on COX-1 in platelets, permanently inactivating the enzyme and preventing thromboxane A2 synthesis. This reduces platelet activation and aggregation, thereby decreasing thrombotic events. At low doses (typically 75–325 mg daily), antiplatelet effects predominate over anti-inflammatory effects.
Approved indications
- Primary prevention of cardiovascular events
- Secondary prevention of myocardial infarction and stroke
- Atrial fibrillation for stroke prevention
Common side effects
- Gastrointestinal bleeding
- Dyspepsia
- Intracranial hemorrhage
- Allergic reactions
Key clinical trials
- Screening and Multiple Intervention on Lung Epidemics (PHASE2)
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Aspirin to Target Arterial Events in Chronic Kidney Disease (PHASE3)
- AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms (PHASE3)
- Adjuvant Low Dose Aspirin in Colorectal Cancer (PHASE3)
- A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low-dose acetylsalicylic acid CI brief — competitive landscape report
- Low-dose acetylsalicylic acid updates RSS · CI watch RSS
- Barcelona Institute for Global Health portfolio CI